免疫检查点（checkpoint）是指在免疫细胞上表达、能调节免疫激活程度的一系列分子，它们对防止自身免疫（免疫功能发生异常，对正常细胞发动攻击）作用的发生，起着重要作用。
人体的免疫功能收到激发时会活化，但不会过度活化，因为”免疫检查点分子“的重要功能之一就是类似汽车的刹车系统，在免疫系统活化时能够及时”刹车“，使免疫系统的活化保持在正常的范围之内，这样，免疫系统就不会过度活化。
免疫检查点分子的表达和功能异常是很多疾病发生的重要原因之一，比如免疫检查点分子过度表达或功能过强，免疫功能受到抑制，机体的免疫力就低下；反之，免疫检查点分子的这种免疫抑制功能如果太差，机体的免疫功能也会异常。
肿瘤细胞会表达一些物质，来激活免疫检查点，后者一旦被激活，就如同踩下”刹车“，使抗原不能被提呈至T细胞，阻断了肿瘤免疫环中的提呈抗原过程，从而抑制T细胞的免疫功能，自己就能逃脱监视、存活下来。
| 靶点 | 产品货号 | 产品名称 |
|
PD1-PDL1
|
GM-81957AB
|
Anti-Canine_PD1 mIgG2a Antibody(4F12-E6)
|
|
PD1-PDL1
|
GM-79817AB
|
Anti-PD-L2 hIgG1 Antibody(Hz25G4-1.1)
|
|
PD1-PDL1
|
GM-32251AB
|
Anti-H_PDCD1LG2 mIgG1 Antibody(3G2)
|
|
PD1-PDL1
|
GM-60293AB
|
Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)
|
|
PD1-PDL1
|
GM-52674AB
|
Anti-PD1 hIgG4 Antibody(Pembrolizumab)
|
|
PD1-PDL1
|
GM-28957AB
|
Anti-H_PDCD1(PD1) hIgG1 Antibody(Budigalimab)
|
|
PD1-PDL1
|
GM-86950AB
|
Anti-Mouse PD-L1 mIgG1 Antibody(10F.9G2)
|
|
PD1
|
GM-86859MAB
|
Anti-PD-1 hIgG4 Reference Antibody (Torbio)
|
|
PD1
|
GM-87759MAB
|
Anti-PD1 hIgG4 Reference Antibody (Nivbio)
|
|
PD1
|
GM-87802MAB
|
Anti-PD1 hIgG4 Reference Antibody (Pembio)
|
|
PD1
|
GM-87803MAB
|
Anti-PD1 hIgG4 Reference Antibody(Cambio)
|
|
CD40
|
GM-86199AB
|
Anti-H_CD40 hIgG1 Antibody(ravagalimab)
|
|
CD40
|
GM-83977AB
|
Anti-H_CD40L hIgG1 Antibody(dapirolizumab)
|
|
CD40
|
GM-83978AB
|
Anti-H_CD40L hIgG1 Antibody(frexalimab)
|
|
CD40
|
GM-24025AB
|
Anti-H_CD40 hIgG1 Antibody(APX005M)
|
|
OX40
|
GM-82533AB
|
Anti-OX40L hIgG4 Antibody(Amlitelimab)
|
|
OX40
|
GM-23373AB
|
Anti-H_OX40 hIgG2 Antibody(Ivuxolimab)
|
|
Lag3
|
GM-51650AB
|
Anti-Lag3 hIgG4 Antibody(Relatlimab)
|
|
Lag3
|
GM-51647AB
|
Anti-Lag3 hIgG4 Antibody(IMP-7)
|
|
Lag3
|
GM-28753AB
|
Anti-H_LAG3 hIgG4 Antibody(Mavezelimab)
|
|
CD27-CD70
|
GM-24024AB
|
Anti-H_CD70 hIgG1 Antibody(Cusatuzumab)
|
|
CD27-CD70
|
GM-31740AB
|
Anti-H_CD274(PDL1) hIgG1 Antibody(Atezolizumab)
|
|
CD47-SIRPα
|
GM-27657AB
|
Anti-CD47 hIgG4 Antibody(5F9)
|
|
CD28
|
GM-52277AB
|
Anti-CD28 hIgG4 Antibody(FR104)
|
|
CD28
|
GM-27197AB
|
Anti-H_CD28 hIgG4 Antibody(Theralizumab)
|
|
CD112-CD112R
|
GM-30125AB
|
Anti-H_NECTIN2(CD112) hIgG1 Antibody
|
|
CD112-CD112R
|
GM-48167AB
|
Anti-CD112R hIgG1 Antibody(SRF813)
|
|
HVEM
|
GM-49928AB
|
Anti-TNFRSF14(HVEM) hIgG4 Antibody
|
|
TREM
|
GM-30244AB
|
Anti-TREM2 hIgG1 Antibody
|
|
TREM
|
GM-22998AB
|
Anti-H_TREM2 Rat_IgG2b Antibody
|
|
TREM
|
GM-48593AB
|
Anti-H_TREM2 hIgG4 Antibody
|
|
HAVCR2(TIM3)
|
GM-50627AB
|
Anti-TIM3 hIgG2 Antibody(M6903)
|
|
HAVCR2(TIM3)
|
GM-27128AB
|
Anti-H_HAVCR2(TIM3) hIgG4 Antibody(Sabatolimab)
|
|
BTLA-HVEM
|
GM-50103AB
|
Anti-BTLA hIgG4 Antibody(22B3)
|
|
BTLA-HVEM
|
GM-28675AB
|
Anti-BTLA hIgG4 Antibody(Icatolimab)
|
|
CD200-CD200R
|
GM-48495AB
|
Anti-H_CD200 hIgG Antibody(Samalizumab)
|
|
CD200-CD200R
|
GM-48346AB
|
Anti-H_CD200R hIgG1 Antibody(huDX182)
|
|
CD200-CD200R
|
GM-48237AB
|
Anti-CD200R hIgG4 Antibody(I-4P)
|
|
CD200-CD200R
|
GM-48240AB
|
Anti-CD200R hIgG4 Antibody
|
|
CTLA4:CD80:CD86
|
GM-46075AB
|
Anti-H_CD80 hIgG1 Antibody(Galiximab)
|
|
CTLA4:CD80:CD86
|
GM-27203AB
|
Anti-H_CTLA-4 hIgG1 Antibody(Ipilimumab)
|
|
CTLA4
|
GM-87752AB
|
Anti-mouse CTLA4 mIgG2a Antibody(9D9)
|
|
CTLA4
|
GM-87801MAB
|
Anti-CTLA4 hIgG1 Reference Antibody (Ipibio)
|
|
SIGLEC8
|
GM-28730AB
|
Anti-H_SIGLEC8 hIgG1 Antibody(1H10)
|
|
4-1BB
|
GM-26840AB
|
Anti-H_4-1BB hIgG2 Antibody(Utomilumab)
|
|
4-1BB
|
GM-28954AB
|
Anti-H_TNFRSF9(4-1BB) hIgG4 Antibody (Urelumab)
|
|
SIGLEC15
|
GM-24717AB
|
Anti-Siglec15 mIgG2a Antibody(5G12)
|
|
TIGIT-PVR-CD155
|
GM-24029AB
|
Anti-H_Tigit hIgG1 Antibody(Vibostolimab)
|
|
TIGIT-PVR-CD155
|
GM-27659AB
|
Anti-H_PVRIG hIgG1 Antibody
|
|
SLC39A6
|
GM-26839AB
|
Anti-H_SLC39A6 hIgG1 Antibody(Ladiratuzumab)
|
|
SIGLEC9
|
GM-31414AB
|
Anti-siglec9 mIgG1 Antibody(2D4)
|
|
VTCN1(B7H4)
|
GM-24028AB
|
Anti-H_B7H4(VTCN1) hIgG1 Antibody(FPA150)
|
|
VTCN1(B7H4)
|
GM-86662MAB
|
Anti-H_B7H4 hIgG1 Reference Antibody(FPA150)
|
|
CD276(B7H3)
|
GM-24026AB
|
Anti-H_CD276(B7H3) hIgG1 Antibody（enoblituzumab）
|
|
ITPRIPL1
|
GM-87827AB
|
Anti-H_ITPRIPL1 mIgG1 Antibody(13B7A6H3)
|
|
B7H3
|
GM-87345MAB
|
Anti-CD276(B7H3) hIgG1 Reference Antibody(Ifibio)
|
|
SIRPA
|
GM-87750AB
|
Anti-mouse SIRPA Monoclonal Antibody(p84)
|
| 靶点 | 产品货号 | 产品名称 |
|
PD1-PDL1
|
GM-81957AB
|
Anti-Canine_PD1 mIgG2a Antibody(4F12-E6)
|
|
PD1-PDL1
|
GM-79817AB
|
Anti-PD-L2 hIgG1 Antibody(Hz25G4-1.1)
|
|
PD1-PDL1
|
GM-32251AB
|
Anti-H_PDCD1LG2 mIgG1 Antibody(3G2)
|
|
PD1-PDL1
|
GM-60293AB
|
Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)
|
|
PD1-PDL1
|
GM-52674AB
|
Anti-PD1 hIgG4 Antibody(Pembrolizumab)
|
|
PD1-PDL1
|
GM-28957AB
|
Anti-H_PDCD1(PD1) hIgG1 Antibody(Budigalimab)
|
|
PD1-PDL1
|
GM-86950AB
|
Anti-Mouse PD-L1 mIgG1 Antibody(10F.9G2)
|
|
PD1
|
GM-86859MAB
|
Anti-PD-1 hIgG4 Reference Antibody (Torbio)
|
|
PD1
|
GM-87759MAB
|
Anti-PD1 hIgG4 Reference Antibody (Nivbio)
|
|
PD1
|
GM-87802MAB
|
Anti-PD1 hIgG4 Reference Antibody (Pembio)
|
|
PD1
|
GM-87803MAB
|
Anti-PD1 hIgG4 Reference Antibody(Cambio)
|
|
CD40
|
GM-86199AB
|
Anti-H_CD40 hIgG1 Antibody(ravagalimab)
|
|
CD40
|
GM-83977AB
|
Anti-H_CD40L hIgG1 Antibody(dapirolizumab)
|
|
CD40
|
GM-83978AB
|
Anti-H_CD40L hIgG1 Antibody(frexalimab)
|
|
CD40
|
GM-24025AB
|
Anti-H_CD40 hIgG1 Antibody(APX005M)
|
|
OX40
|
GM-82533AB
|
Anti-OX40L hIgG4 Antibody(Amlitelimab)
|
|
OX40
|
GM-23373AB
|
Anti-H_OX40 hIgG2 Antibody(Ivuxolimab)
|
|
Lag3
|
GM-51650AB
|
Anti-Lag3 hIgG4 Antibody(Relatlimab)
|
|
Lag3
|
GM-51647AB
|
Anti-Lag3 hIgG4 Antibody(IMP-7)
|
|
Lag3
|
GM-28753AB
|
Anti-H_LAG3 hIgG4 Antibody(Mavezelimab)
|
|
CD27-CD70
|
GM-24024AB
|
Anti-H_CD70 hIgG1 Antibody(Cusatuzumab)
|
|
CD27-CD70
|
GM-31740AB
|
Anti-H_CD274(PDL1) hIgG1 Antibody(Atezolizumab)
|
|
CD47-SIRPα
|
GM-27657AB
|
Anti-CD47 hIgG4 Antibody(5F9)
|
|
CD28
|
GM-52277AB
|
Anti-CD28 hIgG4 Antibody(FR104)
|
|
CD28
|
GM-27197AB
|
Anti-H_CD28 hIgG4 Antibody(Theralizumab)
|
|
CD112-CD112R
|
GM-30125AB
|
Anti-H_NECTIN2(CD112) hIgG1 Antibody
|
|
CD112-CD112R
|
GM-48167AB
|
Anti-CD112R hIgG1 Antibody(SRF813)
|
|
HVEM
|
GM-49928AB
|
Anti-TNFRSF14(HVEM) hIgG4 Antibody
|
|
TREM
|
GM-30244AB
|
Anti-TREM2 hIgG1 Antibody
|
|
TREM
|
GM-22998AB
|
Anti-H_TREM2 Rat_IgG2b Antibody
|
|
TREM
|
GM-48593AB
|
Anti-H_TREM2 hIgG4 Antibody
|
|
HAVCR2(TIM3)
|
GM-50627AB
|
Anti-TIM3 hIgG2 Antibody(M6903)
|
|
HAVCR2(TIM3)
|
GM-27128AB
|
Anti-H_HAVCR2(TIM3) hIgG4 Antibody(Sabatolimab)
|
|
BTLA-HVEM
|
GM-50103AB
|
Anti-BTLA hIgG4 Antibody(22B3)
|
|
BTLA-HVEM
|
GM-28675AB
|
Anti-BTLA hIgG4 Antibody(Icatolimab)
|
|
CD200-CD200R
|
GM-48495AB
|
Anti-H_CD200 hIgG Antibody(Samalizumab)
|
|
CD200-CD200R
|
GM-48346AB
|
Anti-H_CD200R hIgG1 Antibody(huDX182)
|
|
CD200-CD200R
|
GM-48237AB
|
Anti-CD200R hIgG4 Antibody(I-4P)
|
|
CD200-CD200R
|
GM-48240AB
|
Anti-CD200R hIgG4 Antibody
|
|
CTLA4:CD80:CD86
|
GM-46075AB
|
Anti-H_CD80 hIgG1 Antibody(Galiximab)
|
|
CTLA4:CD80:CD86
|
GM-27203AB
|
Anti-H_CTLA-4 hIgG1 Antibody(Ipilimumab)
|
|
CTLA4
|
GM-87752AB
|
Anti-mouse CTLA4 mIgG2a Antibody(9D9)
|
|
CTLA4
|
GM-87801MAB
|
Anti-CTLA4 hIgG1 Reference Antibody (Ipibio)
|
|
SIGLEC8
|
GM-28730AB
|
Anti-H_SIGLEC8 hIgG1 Antibody(1H10)
|
|
4-1BB
|
GM-26840AB
|
Anti-H_4-1BB hIgG2 Antibody(Utomilumab)
|
|
4-1BB
|
GM-28954AB
|
Anti-H_TNFRSF9(4-1BB) hIgG4 Antibody (Urelumab)
|
|
SIGLEC15
|
GM-24717AB
|
Anti-Siglec15 mIgG2a Antibody(5G12)
|
|
TIGIT-PVR-CD155
|
GM-24029AB
|
Anti-H_Tigit hIgG1 Antibody(Vibostolimab)
|
|
TIGIT-PVR-CD155
|
GM-27659AB
|
Anti-H_PVRIG hIgG1 Antibody
|
|
SLC39A6
|
GM-26839AB
|
Anti-H_SLC39A6 hIgG1 Antibody(Ladiratuzumab)
|
|
SIGLEC9
|
GM-31414AB
|
Anti-siglec9 mIgG1 Antibody(2D4)
|
|
VTCN1(B7H4)
|
GM-24028AB
|
Anti-H_B7H4(VTCN1) hIgG1 Antibody(FPA150)
|
|
VTCN1(B7H4)
|
GM-86662MAB
|
Anti-H_B7H4 hIgG1 Reference Antibody(FPA150)
|
|
CD276(B7H3)
|
GM-24026AB
|
Anti-H_CD276(B7H3) hIgG1 Antibody（enoblituzumab）
|
|
ITPRIPL1
|
GM-87827AB
|
Anti-H_ITPRIPL1 mIgG1 Antibody(13B7A6H3)
|
|
B7H3
|
GM-87345MAB
|
Anti-CD276(B7H3) hIgG1 Reference Antibody(Ifibio)
|
|
SIRPA
|
GM-87750AB
|
Anti-mouse SIRPA Monoclonal Antibody(p84)
|
免疫检查点（checkpoint）是指在免疫细胞上表达、能调节免疫激活程度的一系列分子，它们对防止自身免疫（免疫功能发生异常，对正常细胞发动攻击）作用的发生，起着重要作用。
人体的免疫功能收到激发时会活化，但不会过度活化，因为”免疫检查点分子“的重要功能之一就是类似汽车的刹车系统，在免疫系统活化时能够及时”刹车“，使免疫系统的活化保持在正常的范围之内，这样，免疫系统就不会过度活化。
免疫检查点分子的表达和功能异常是很多疾病发生的重要原因之一，比如免疫检查点分子过度表达或功能过强，免疫功能受到抑制，机体的免疫力就低下；反之，免疫检查点分子的这种免疫抑制功能如果太差，机体的免疫功能也会异常。
肿瘤细胞会表达一些物质，来激活免疫检查点，后者一旦被激活，就如同踩下”刹车“，使抗原不能被提呈至T细胞，阻断了肿瘤免疫环中的提呈抗原过程，从而抑制T细胞的免疫功能，自己就能逃脱监视、存活下来。
